An Update On DARA Bio
By:
DailyMarkets.com
Posted on September 09, 2010 at 18:05 PM EDT
KRN5500 Data Looks Strong On September 8, 2010, DARA BioSciences (NASDAQ:DARA) presented positive study results from its phase II dose escalation study with KRN5500 at the 13th World Congress on Pain. The multicenter, placebo-controlled phase II study was designed to evaluate the safety and efficacy of KRN5500 for treatment of neuropathic pain in patients with [...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here